Riken Vitamin Co., Ltd. (JP:4526)
:4526
Top Page
Riken Vitamin Co., Ltd.
(4526)
Select Model
Select Model
Rating:82Outperform
Price Target:
¥3,548.00
▲(19.58% Upside)
Action:ReiteratedDate:07/25/25
Riken Vitamin Co., Ltd. achieves a robust overall stock score due to a combination of strong financial performance, attractive valuation, and positive technical indicators. The company's financial health, characterized by solid profitability and low leverage, is complemented by an undervalued stock price and a strong upward price trend. The absence of recent earnings call data or notable corporate events did not impact the score calculation.
Positive Factors
Strong balance sheet
Conservative leverage and a 70% equity ratio provide durable financial flexibility. With D/E of 0.13 and ROE of 11.86% the company can fund operations, absorb shocks, and pursue selective investments without stressing solvency, supporting stability over months.
Negative Factors
Declining operating cash flow
A drop in operating cash flow reduces internal funding available for reinvestment and dividends. If the decline persists, the company may need to cut investment, rely more on working capital adjustments, or constrain growth initiatives over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
Conservative leverage and a 70% equity ratio provide durable financial flexibility. With D/E of 0.13 and ROE of 11.86% the company can fund operations, absorb shocks, and pursue selective investments without stressing solvency, supporting stability over months.
Read all positive factors
Riken Vitamin Co., Ltd. (4526) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥66.70B
Dividend Yield3.63%
Average Volume (3M)91.61K
Price to Earnings (P/E)8.5
Beta (1Y)0.54
Revenue Growth1.78%
EPS Growth19.50%
CountryJP
Employees1,857
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)87.72
Shares Outstanding30,705,100
10 Day Avg. Volume57,120
30 Day Avg. Volume91,606
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)0.93
Price to Sales (P/S)0.77
P/FCF Ratio23.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)284.06
Revenue Forecast (FY)¥101.00B
Riken Vitamin Co., Ltd. Business Overview & Revenue Model
Company Description
Riken Vitamin Co., Ltd. engages in the food ingredient, food application, health care, and chemical businesses in Japan. It offers food emulsifies for use in bread, cake, whipped topping, coffee cream, margarine, tofu, jam, marmalade, ice cream, c...
How the Company Makes Money
Riken Vitamin Co., Ltd. generates revenue through multiple streams, primarily by selling its core products, including vitamins and amino acids, to various industries such as pharmaceuticals, food, and dietary supplements. The company capitalizes o...
Riken Vitamin Co., Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
82
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 95.21B | 95.58B | 91.48B | 88.75B | 79.23B | 77.72B |
| Gross Profit | 30.97B | 31.27B | 29.89B | 27.24B | 25.57B | 22.01B |
| EBITDA | 15.63B | 16.04B | 15.35B | 11.71B | 24.23B | 4.61B |
| Net Income | 8.84B | 9.39B | 8.76B | 6.41B | 21.58B | -1.62B |
Balance Sheet | ||||||
| Total Assets | 112.78B | 113.00B | 118.78B | 105.22B | 102.66B | 106.53B |
| Cash, Cash Equivalents and Short-Term Investments | 20.05B | 22.30B | 23.38B | 19.16B | 17.30B | 19.23B |
| Total Debt | 10.13B | 9.98B | 16.09B | 14.60B | 17.57B | 24.41B |
| Total Liabilities | 33.72B | 33.80B | 42.13B | 33.85B | 36.12B | 59.86B |
| Stockholders Equity | 79.02B | 79.16B | 76.61B | 71.34B | 66.52B | 46.16B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 3.12B | 7.42B | 5.67B | 3.44B | 3.85B |
| Operating Cash Flow | 0.00 | 7.89B | 10.45B | 7.83B | 6.82B | 7.63B |
| Investing Cash Flow | 0.00 | 353.00M | -554.00M | -2.03B | -3.66B | -2.29B |
| Financing Cash Flow | 0.00 | -9.96B | -7.08B | -4.58B | -7.57B | -180.00M |
Riken Vitamin Co., Ltd. Technical Analysis
Positive
2967.00
Price Trends
2968.38
Negative
2928.83
Positive
2840.86
Positive
Market Momentum
4.43
Negative
54.21
Neutral
82.41
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4526, the sentiment is Positive. The current price of 2967 is above the 20-day moving average (MA) of 2874.55, below the 50-day MA of 2968.38, and above the 200-day MA of 2840.86, indicating a neutral trend. The MACD of 4.43 indicates Negative momentum. The RSI at 54.21 is Neutral, neither overbought nor oversold. The STOCH value of 82.41 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4526.
Riken Vitamin Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | ¥66.70B | 8.46 | ― | 3.63% | 1.78% | 19.50% | |
64 Neutral | ¥12.51B | 5.91 | ― | 3.94% | 11.47% | 29.21% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | ¥4.52T | 20.92 | 9.46% | 1.32% | 1.99% | -18.79% | |
59 Neutral | ¥427.56B | 10.37 | ― | 2.42% | 2.33% | -8.76% | |
59 Neutral | ¥36.80B | 8.05 | ― | 3.84% | 6.49% | 31.81% | |
57 Neutral | ¥311.78B | 10.01 | ― | 1.45% | 20.02% | ― |
* Consumer Defensive Sector Average
JP:4526
Riken Vitamin Co., Ltd.
2,925.00
584.28
24.96%
JP:2802
Ajinomoto Co
4,652.00
1,870.57
67.25%
JP:2264
Morinaga Milk Industry Co., Ltd.
4,981.00
1,902.17
61.78%
JP:2607
Fuji Oil Holdings, Inc.
3,627.00
649.91
21.83%
JP:2927
AFC-HD AMS Life Science Co., Ltd.
883.00
86.87
10.91%
JP:3139
Lacto Japan Co., Ltd.
3,675.00
884.48
31.70%
Riken Vitamin Co., Ltd. Corporate Events
Riken Vitamin Nears Full Use of ¥2 Billion Share Buyback Authorization
Mar 24, 2026
Riken Vitamin Co., Ltd. has completed an additional repurchase of 53,300 shares of its common stock on the Tokyo Stock Exchange between March 1 and March 23, 2026, at a total cost of ¥156,067,693. This latest transaction forms part of a broad...
Riken Vitamin Advances Toward Completion of ¥2 Billion Share Buyback Program
Mar 2, 2026
Riken Vitamin Co., Ltd. has reported progress on its ongoing share repurchase program, acquiring 57,300 shares of its common stock on the Tokyo Stock Exchange between February 1 and February 28, 2026, at a total cost of 179,067,993 yen. This buyba...
Riken Vitamin Profit Hit by Overseas Slump and Asbestos Costs, Net Income Buoyed by Share Sales
Feb 12, 2026
Riken Vitamin Co., Ltd. reported that consolidated net sales edged down year on year as growth in domestic food and chemical operations was outpaced by a sharp decline in overseas sales, which swung to an operating loss amid weaker gross profit an...
Riken Vitamin Slashes Full-Year Profit Outlook on Overseas Weakness and Asbestos Costs
Feb 12, 2026
Riken Vitamin Co., Ltd. has lowered its consolidated full-year forecast for the fiscal year ending March 31, 2026, cutting projected net sales from ¥100 billion to ¥96 billion and trimming expected profit attributable to owners of parent...
Riken Vitamin Cuts Profit Outlook Despite Solid Balance Sheet and Higher Dividends
Feb 12, 2026
Riken Vitamin reported nine‑month consolidated net sales to December 31, 2025 of ¥72.5 billion, edging down 0.5% year on year, while operating profit fell 24.2% to ¥5.7 billion and ordinary profit dropped 22.3%. Profit attributable...
Riken Vitamin Reports Progress on Ongoing Share Buyback Program
Feb 2, 2026
Riken Vitamin Co., Ltd., a Tokyo Stock Exchange Prime Market-listed food ingredients and vitamin producer, continues to actively manage its capital structure through share repurchases authorized by its board in April 2025. During the period from J...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.